logo
Share SHARE
FONT-SIZE Plus   Neg

AMAG Pharma Says Ferumoxytol Gets European Marketing Authorization To Treat IDA

AMAG Pharmaceuticals Inc. (AMAG) announced that the European Commission has granted marketing authorization for ferumoxytol, an intravenous or IV iron therapy to treat iron deficiency anemia or IDA in adult patients with chronic kidney disease or CKD.

The company said that the marketing authorization followed a positive opinion, issued on April 19, 2012, by the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency.

Ferumoxytol was approved for the same indication in the US under the brand name Feraheme in June 2009.

The company said that the marketing authorization is valid in the current European Union Member States as well as in Iceland and Norway, and is based on data obtained from an extensive clinical development program. Takeda Pharmaceutical Company Limited, AMAG's partner in Europe, plans to launch ferumoxytol in Europe under the brand name Rienso in 2012.

The company also said that the EU marketing authorization triggers a $15 million milestone payment to AMAG from Takeda; the first commercial sale of Riensoin Europe will trigger another $15 million milestone payment to AMAG. Additionally, AMAG is entitled to receive tiered, double-digit royalties on sales of Rienso in the licensed territories.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
French telecom equipment maker Alcatel-Lucent, which is being acquired by Finnish network equipment maker Nokia Corp., reported higher profit in its fourth quarter with strong revenue growth. All segments, mainly Next-generation technologies, and all regions, including North America and Asia, recorded higher revenues. The company also announced the successful completion of the Shift Plan. Shares of Rio Tinto Plc. were losing around 7 percent in the morning trading in London after the mining giant reported a loss for its fiscal year 2015, compared to profit last year, amid steep decline in commodity prices. Further, the company announced flat dividend, and said it is no longer appropriate to maintain the progressive dividend policy. French lender Societe Generale SA reported Thursday higher net profit in its fourth quarter, while operating income declined sharply amid higher litigation provision and lower net banking income. However, fiscal 2015 was marked by good operating performances in all the businesses. Citing the annual results, the company lifted its dividend.
comments powered by Disqus
RELATED NEWS
Trade AMAG now with 
Follow RTT